SKIPPAIN - Speed of Onset of SecuKinumab-Induced Relief From Pain in Patients With AxIal SpoNdyloarthritis

PHASE3CompletedINTERVENTIONAL
Enrollment

383

Participants

Timeline

Start Date

June 30, 2017

Primary Completion Date

February 15, 2019

Study Completion Date

February 15, 2019

Conditions
Spondyloarthritis
Interventions
BIOLOGICAL

AIN457

anti IL-17a monoclonal antibody

DRUG

AIN457 Placebo

Placebo matching AIN457

Trial Locations (66)

1020

Novartis Investigative Site, Brussels

1413

Novartis Investigative Site, Sofia

1505

Novartis Investigative Site, Sofia

1750

Novartis Investigative Site, Sofia

4000

Novartis Investigative Site, Liège

Novartis Investigative Site, Plovdiv

4031

Novartis Investigative Site, Basel

8000

Novartis Investigative Site, Burgas

10000

Novartis Investigative Site, Zagreb

Novartis Investigative Site, Zagreb

10138

Novartis Investigative Site, Tallinn

10600

Novartis Investigative Site, Plasencia

27003

Novartis Investigative Site, Lugo

28850

Novartis Investigative Site, Torrejón de Ardoz

30599

Novartis Investigative Site, Plzen-Bory

32005

Novartis Investigative Site, Ourense

37134

Novartis Investigative Site, Verona

39300

Novartis Investigative Site, Torrelavega

41009

Novartis Investigative Site, Seville

41013

Novartis Investigative Site, Seville

45100

Novartis Investigative Site, Kuovola

46010

Novartis Investigative Site, Valencia

46014

Novartis Investigative Site, Valencia

50406

Novartis Investigative Site, Tartu

51000

Novartis Investigative Site, Rijeka

54636

Novartis Investigative Site, Thessaloniki

63800

Novartis Investigative Site, Brno

70100

Novartis Investigative Site, Kuopio

80010

Novartis Investigative Site, Pärnu

115093

Novartis Investigative Site, Moscow

420097

Novartis Investigative Site, Kazan'

426009

Novartis Investigative Site, Izhevsk

664046

Novartis Investigative Site, Irkutsk

150 06

Novartis Investigative Site, Prague

681 00

Novartis Investigative Site, Alexandroupoli

564 29

Novartis Investigative Site, Thessaloniki

115 27

Novartis Investigative Site, Athens

145 61

Novartis Investigative Site, Athens

D03 VX82

Novartis Investigative Site, Dublin

D04 T6F

Novartis Investigative Site, Dublin

LV 3401

Novartis Investigative Site, Liepāja

LV 1002

Novartis Investigative Site, Riga

LV 2164

Novartis Investigative Site, Riga

LT 50161

Novartis Investigative Site, Kaunas

LT-50128

Novartis Investigative Site, Kaunas

02 495

Novartis Investigative Site, Warsaw

85 168

Novartis Investigative Site, Bydgoszcz

81 756

Novartis Investigative Site, Sopot

87-100

Novartis Investigative Site, Torun

00-874

Novartis Investigative Site, Warsaw

04 305

Novartis Investigative Site, Warsaw

53-224

Novartis Investigative Site, Wroclaw

03203

Novartis Investigative Site, Elche

03600

Novartis Investigative Site, Elda

07198

Novartis Investigative Site, Mallorca

Unknown

Novartis Investigative Site, Galdakao

08041

Novartis Investigative Site, Barcelona

113 65

Novartis Investigative Site, Stockholm

182 88

Novartis Investigative Site, Danderyd

SE 302 66

Novartis Investigative Site, Halmstad

SE 871 31

Novartis Investigative Site, Härnösand

ST6 7AG

Novartis Investigative Site, Stoke-on-Trent

L9 7AL

Novartis Investigative Site, Liverpool

PL6 8DH

Novartis Investigative Site, Plymouth

WA5 1QG

Novartis Investigative Site, Warrington

WV10 0QP

Novartis Investigative Site, Wolverhampton

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY